Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048932 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,795
- Enrollment target
NCT00048932: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00048932 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,795 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048932, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,795 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.
Primary Outcome
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is
Interventions
- DRUG Double-blind Abatacept
- DRUG Double-blind Placebo
- DRUG Open-label Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,795 participants |
| Start Date | 2002-12 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
What the finished NCT00048932 record still lists
NCT00048932 is an interventional study that assigns participants to a tested intervention. Its 1,795 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 3 interventions - of which Double-blind Abatacept is the first listed.
NCT00048932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00048932 about?
NCT00048932 is a clinical study titled "A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis". The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.
What is the current status of trial NCT00048932?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,795 participants. The study started on 2002-12. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00048932?
The interventions under investigation include: Double-blind Abatacept (DRUG), Double-blind Placebo (DRUG), Open-label Abatacept (DRUG).
Who is sponsoring clinical trial NCT00048932?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00048932's enrollment target sits among peer trials
1,795 125th of 2000 higher than 1,876 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia